HIV治愈试验分析性治疗中断期间病毒学控制的影响因素:个体水平数据汇总分析
该研究汇总6项含分析性治疗中断的干预试验的91名参与者数据,用Cox回归分析可检测病毒血症和病毒学控制丧失的影响因素。高总HIV-DNA、完整前病毒DNA、诊断至启动ART时间≥1年及使用组蛋白去乙酰化酶抑制剂与更短时间相关,而3BNC117敏感病毒者启动ART时接受广谱中和抗体治疗有延迟趋势但未达统计学显著。
要点
- 总HIV-DNA≥750 copies/mL与可检测病毒血症时间更短相关(HR=1.98)。
- 完整前病毒DNA≥80 copies/10^6 CD4+ T细胞与可检测病毒血症时间更短相关(HR=1.67)。
- 诊断至启动ART≥1年及使用组蛋白去乙酰化酶抑制剂预测病毒学控制丧失更短。
核心结论
- 早期启动ART和低HIV储存库对分析性治疗中断者病毒反弹时间有积极影响,并为实现病毒学控制的治疗干预提供新见解。
研究设计与样本
- 对6项含分析性治疗中断的干预试验进行个体水平数据汇总分析,共纳入91名参与者,采用Cox比例风险回归分析影响因素。
主要发现
- 总HIV-DNA≥750 copies/mL与可检测病毒血症时间更短相关(HR=1.98;95%CI 1.22-3.22)。
- 完整前病毒DNA≥80 copies/10^6 CD4+ T细胞与可检测病毒血症时间更短相关(HR=1.67;95%CI 1.08-2.58)。
- 总HIV-DNA≥750 copies/10^6 CD4+ T细胞预测病毒学控制丧失时间更短(HR=1.64;95%CI 1.01-2.67)。
- 诊断至启动ART时间≥1年预测病毒学控制丧失时间更短(HR=1.56;95%CI 1.02-2.39)。
- 接受组蛋白去乙酰化酶抑制剂预测病毒学控制丧失时间更短(HR=2.22;95%CI 1.12-4.41)。
关键数值与推荐
- 可检测病毒血症定义为血浆HIV-RNA≥50 copies/mL。
- 病毒学控制丧失定义为连续2次血浆HIV-RNA≥5000 copies/mL或重启ART。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Achieving antiretroviral therapy (ART)-free virologic control remains a central goal in human immunodeficiency virus (HIV) cure research. To identify factors associated with time to detectable viremia and time to loss of virologic control, we conducted a pooled analysis of 6 interventional trials that included analytical ART interruption. METHODS: We determined factors influencing time to detectable viremia (plasma HIV-RNA ≥50 copies/mL) and loss of virologic control (2 consecutive measurements of plasma HIV-RNA ≥5000 copies/mL or restart of ART) using Cox proportional hazard regression. RESULTS: Among the 91 included participants we found that high levels of total HIV-DNA (≥750 copies/mL) and intact proviral DNA (≥80 copies/106 CD4+ T cells) were both associated with shorter time to detectable viremia (hazard ratio [HR] = 1.98; 95% confidence interval [CI], 1.22-3.22 and HR = 1.67; 95% CI, 1.08-2.58, respectively). Total HIV-DNA ≥750 copies/106 CD4+ T cells also predicted shorter time to loss of virologic control (HR = 1.64; 95% CI, 1.01-2.67), as did longer time (≥1 year) from HIV diagnosis to ART start (HR = 1.56; 95% CI, 1.02-2.39). Having received histone deacetylase inhibitors predicted shorter time to loss of virologic control (HR = 2.22; 95% CI, 1.12-4.41), while broadly neutralizing anti-HIV-1 antibody treatment at ART initiation of individuals harboring 3BNC117-sensitive viruses trended towards delayed time to loss of virologic control (HR = 0.32; 95% CI, .10-1.01). CONCLUSIONS: Our findings highlight the positive impact of early ART and low HIV reservoirs on time to rebound among people undergoing analytical treatment interruption and provides new insight into therapeutic interventions aimed at achieving virologic control.
引用
- Klastrup V, Gunst JD, Rasmussen TA, et al. Factors Influencing Virologic Control During Analytical Treatment Interruptions in HIV Cure Trials-a Pooled Analysis of Individual-Level Data. J Infect Dis. 2025. PMID: 40139936. doi:10.1093/infdis/jiaf163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。